Cuenca DJ, Esperón LI

Language: Spanish
References: 19
Page: 198-202
PDF size: 146.11 Kb.

ABSTRACT

Objective: To compare the efficiency of two analgesic therapies, one of them based on central analgesic derivated opioid partial agonist (CADOPA) plus NSAID, (non-steroidal anti-inflammatory drug), administered as in-advance-analgesia at premeditation, versus an scheduled given NSAID scheme plus another NSAID in response to analgesic claim in the postoperative period, both being indicated by the surgical service from an emergency/general hospital. Besides, the economic cost of the two analgesic drug schemes used, was evaluated. Material and methods: It is a simple randomized, time-course followed, prospective and comparative study, of 40 patients that were accepted by the Surgery General Service from the Hospital, by abdominal surgery, which had an SA physical score E I and II B; distributed in two groups. Group A: 300 mcg IV of Buprenorphine was administered ten minutes previous to the beginning of the surgery Group B: Metamizol 1 g IV was administered 20 minutes before the surgical procedure was completed and then every 8 hrs. Ketorolaco 30 mg or Metamizol 1 g IV was administered in both groups according to patient’s analgesic claims and indications of the surgical service in the postoperative period. Heart rate, mean blood pressure, respiratory rate and pain by VAS (Analog Visual Scale) were evaluated at 4, 8, 24, 32 and 48 hours after surgery; relief of pain sensibility and economic cost of whole analgesic requirement in each group were also evaluated. Results: The differences in the hemodynamic variables, respiratory rate and score from the VAS for the pain were not statistically significative between the two groups; nevertheless, statistical significant differences were observed in the number of patients that experienced relief of pain sensibility at 48 hours after the surgery: group A 95% (19/20), and in group B 50% (10/20), p < 0.05. Also, a significant difference was found regarding the number of analgesic doses claimed by the patients in the postoperative period, with lower number of doses in group A; furthermore, whole cost of the analgesic treatment in group A was $550.00, while in group B was $1,270.00. Conclusion: Although the two postoperative analgesic treatment alternatives are appropriate, the management with Buprenorphine at the preanesthesic medication results in more patients with less pain after surgery, which suggests a higher economic benefits either for the patient and for the hospital.

REFERENCES

1. Ramírez A, Burkle J. Dolor agudo postoperatorio, su frecuencia y su manejo. Rev Mex Anest 1992;15:14-17.

2. Bonica JJ. Definitions and taxonomy of pain. In: Bonica JJ. editor. The management of pain. Philadelphia: Lea & Febiger 1990:457-472.

3. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-1233.

4. Sinatra RS, Hord AH. Neurochemistry modulation of pain. In: Ginsberg B, Preble LM, editor. Acute Pain: Mechanisms and Management. Mosby year book ST Louis 1992:32-43.

5. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-314.

6. Scott LJ, Lamb HM. Rofecoxib. Drugs 1999;58:499-507.

7. Oden RV. Acute postoperative pain: Incidence, severity and the etiology of inadequate treatment. Anaesth Clin N Am 1989;7:101-132.

8. Sriwantakul K, Kelvie W, Lasagna L, Calimlim J, Weis O, Mehta G. Studies with of different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 1983;34:234-239.

9. Management of Acute Pain: A practical guide. International Association for the Study of Pain. IASP publications. Seattle 1992:1-10.

10. Sriwatanakul K, Kelvie W, Lasagna L, Calimlim J, Weis O, Mehta G. Studies with different types of visual analogous scales for measurement of pain. Clin Pharmacol Ther 1983;34:234-239.

11. Wall PD. The prevention of postoperative pain. Pain 1988;33:289-290.

12. Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ. Characterizations of rofecoxib as a cyclooxygenase- 2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-347.

13. Pairet M, Netter P. Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations. Therapie 1999; 54:433-45.

14. Malmstrom K, Daniels S, Kotey P, Seidenberg BC, Desjardins PJ. Comparison of rofecoxib and celecoxib, two cyclooxygenase- 2 inhibitors, in postoperative dental pain: a randomized, placebo and active-comparator-controlled clinical trial. Clin Ther 1999;21:1653-1663.

15. Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2- specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Pharmacol Ther 1999;21:943-953.

16. Celebioglu B, et al. Extradural buprenorfine and breast feeding after caesarian, section. Br J Anaesth 1998;80:271-274.

17. Lille-Fuentes R. Analgesia postoperatoria con Buprenorfina sublingual. Rev Mex Anest 1990;5:108-111.

18. Romero GA. Estudio comparativo Nalbufina vs Buprenorfina para control del dolor postoperatorio y efectos colaterales. Rev Mex Anest 1998;5:151-155.

19. Guevara U, De Lille FR, Roa AL. Buprenorfina IM para el control del dolor postoperatorio. Rev Mex Anest 1992;15:151-155.